EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis

Hendy Kristyanto, Sagrario Rey Torre, Anna Cunney, Kristina Dunder, Margareta Bego, Bruno Sepodes, Thomas Castelnovo

British Journal of Dermatology · 17.10.2025 · 193 (5) · 996-998

DOI: 10.1093/bjd/ljaf259 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 28.06.2025. Verfasst von Hendy Kristyanto und 6 weiteren Autor:innen. Beteiligte Einrichtung: European Medicines Agency, Domenico Scarlattilaan 6, 1083HS Amsterdam, the Netherlands. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) and prurigo nodularis (PN) are chronic inflammatory skin diseases that are characterized by intense pruritus. Nemolizumab is the first interleukin-31 blocking agent approved in the EU for the treatment of moderate-to-severe AD and PN. This article summarizes the key benefits and risks associated with nemolizumab and provides perspectives on the additional value of nemolizumab in the treatment armamentarium.

Autor:innen und Institutionen

  • European Medicines Agency, Domenico Scarlattilaan 6, 1083HS Amsterdam, the Netherlands.
  • Swedish Medical Products Agency, Dag Hammarskjolds Vag 42, Uppsala Science Park, 752 37 Uppsala, Sweden.
  • Agency for Medicinal Products and Medical Devices of Croatia, Ksaverska Cesta 4, 10000 Zagreb, Croatia.
  • Faculdade de Farmácia da Universidade de Lisboa, Avenida Professor Gama Pinto 1649-003 Lisboa, Portugal.

Zitieren

APA

Kristyanto, H., Rey Torre, S., Cunney, A., Dunder, K., Bego, M., Sepodes, B., & Castelnovo, T. (2025). The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis. British Journal of Dermatology, 193(5), 996-998. https://doi.org/10.1093/bjd/ljaf259

Vancouver

Kristyanto H, Rey Torre S, Cunney A, Dunder K, Bego M, Sepodes B, et al. The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis. British Journal of Dermatology. 2025;193(5):996-998. doi:10.1093/bjd/ljaf259

BibTeX
@article{Kristyanto2025,
  author = {Kristyanto, Hendy and Rey Torre, Sagrario and Cunney, Anna and Dunder, Kristina and Bego, Margareta and Sepodes, Bruno and Castelnovo, Thomas},
  title = {The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis},
  journal = {British Journal of Dermatology},
  year = {2025},
  volume = {193},
  number = {5},
  pages = {996--998},
  doi = {10.1093/bjd/ljaf259}
}
Kostenlos starten →